SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Ainos, Inc. (AIMD) News

Follow Ainos, Inc. (AIMD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol AIMD Asset equity Sector Markets 90 days 7 Last 1.27 Updated Sep 29, 2026, 12:01 PM UTC Open live news feed Open AIMD chart & news
L Ainos, Inc. (AIMD) Delivers 1,400 AI Nose Units Under $2.1M ASE Deal Ainos completed delivery of 1,400 AI Nose systems to ASE under a $2.1M, three-year agreement, enabling revenue recognition beginning in Q3 2026. The parties are discussing a larger second-phase deployment under an existi EARNINGS | Sep 29, 2026, 12:01 PM UTC L Ainos Completes Delivery of 1,400 AI Nose Systems to ASE Under $2.1 Million, Three-Year Contract Preparations underway for a larger-scale second-phase deployment specified in the existing MOU, building on first-phase deployment experienceAdvanced packaging deployment marks a major step for Ainos' Chemical Intelligen NEWS | Sep 29, 2026, 12:01 PM UTC L Ainos Details Partner-Funded VELDONA Development and Revenue Opportunities, Reinforcing Focus on Chemical Intelligence Initial license payment tied to near-term contractual delivery; additional payment opportunities may arise during development, before drug approvalPartner assumes assigned clinical and regulatory funding and execution, r NEWS | Sep 28, 2026, 12:08 PM UTC L Ainos Grants Global VELDONA License to BioPhoenix; Upfront $600,000, Fees Up to $10 Million Ainos entered into a Global Exclusive License Agreement with BioPhoenix covering its VELDONA low-dose oral interferon alpha platform for Sjögren’s Disease and thrombocytopenia. The worldwide, transferable license allows NEWS | Sep 28, 2026, 12:05 PM UTC L Ainos, Inc. (AIMD) Signs VELDONA License With Potential $10M Framework Ainos signed a VELDONA license with BioPhoenix, outlining a potential $10M collaboration framework. BioPhoenix will fund and execute development for two initial indications; the $10M is conditional and excludes developme NEWS | Sep 24, 2026, 12:03 PM UTC L Ainos and BioPhoenix Sign VELDONA License Agreement, Establishing a Potential $10 Million Collaboration Framework Partner-funded development marks an important milestone for VELDONA, with BioPhoenix funding and advancing clinical and regulatory development for two initial indicationsDevelopment funding is additional to the framework NEWS | Sep 24, 2026, 12:02 PM UTC L Ainos secures three Japanese robotics patents for chemical perception Ainos says new patents cover electronic nose integration with robotics. It also cites a portfolio of 124 patent assets worldwide across chips, sensing architectures, chemical molecules and real-world applications. EQUITY | Sep 09, 2026, 12:01 PM UTC L AIMD Expands Smell AI Ainos expands smell AI into patient-level breath intelligence, according to VASRO Research EQUITY | Jun 22, 2026, 01:02 PM UTC